Rahoton Shari'a na Cikakken Amsa na Dogon Lokaci a Ciwon Kansa na Hepatocellular ga Kwayoyin CAR T na GPC3 (CT011)

CT011 wani samfurin ƙwayoyin GPC3 CAR T ne da aka yi niyya don magance cutar kansar hanta (HCC). CT011 ya sami izinin IND daga NMPA a shekarar 2019 don maganin marasa lafiya da ke da ciwon daji mai kyau na GPC3 wanda shine gwajin IND na farko da China ta yi don maganin ƙwayoyin T na CAR akan ciwon daji mai ƙarfi.

A ranar 18 ga Agusta, 2022, CARsgen Therapeutics ta sanar da cewa an buga wani rahoto na shari'a, mai taken "Maganin Dogon Lokaci na Ciwon Kanjamau na Hepatocellular da ke Ci gaba da Yaɗuwa ga Kwayoyin T-Cells na Glypican-3 da Sorafenib, Rahoton shari'a", a cikin Frontiers in Immunology.

Wannan lamari ya nuna wani namiji ɗan Asiya mai shekaru 60 da ke fama da cutar hepatitis B (HBV) wanda aka yi masa tiyata a watan Mayu na 2018. A watan Agusta na 2018, sake kamuwa da cutar kansar hanta da kuma ciwon huhu ya faru bayan tiyatar, sannan aka yi masa transarterial chemoembolization (TACE) don magance raunukan hanta da kuma cirewar ciki don magance ciwon huhu. Bayan watanni biyu, ya ci gaba kuma an shigar da shi cikin gwajin asibiti. Bayan rajista, an yi wa majinyacin leukapheresis don kera ƙwayoyin T-cell na CAR-GPC3. Kwanaki bakwai bayan leukapheresis, majinyacin ya fara karɓar 400 mg na sorafenib sau biyu a rana. Majinyacin ya karɓi zagaye 4 na maganin ƙwayoyin T-CAR-GPC3 (CT011) kuma an raba kowane zagaye zuwa jiko biyu. Kafin kowane zagaye na maganin CT011, an yi lymphopletion. Jimillar 4×10⁹An saka ƙwayoyin T na CAR-GPC3.

An yi haƙuri da maganin haɗin gwiwa na CT011 da sorafenib sosai. Wannan majiyyaci ya sami wasu martani (PR) daga wata na 3 kuma ya sami CR a cikin wata na 12 bayan zagayen farko na maganin CT011. Ciwon bai sami ci gaba ba na tsawon watanni 36 kuma ya ci gaba da kasancewa a matsayin CR na tsawon fiye da watanni 24 bayan allurar farko.

A gwargwadon iliminmu, wannan shine karo na farko da aka ruwaito da aka samu da cutar CR bayan hadewar kwayoyin halittar CAR T tare da masu hana tyrosine kinase. Sakamakon asibiti ya nuna cewa hadewar maganin GPC3 CAR T-cell da Sorafenib na iya zama sabuwar hanya mai kyau ga marasa lafiya da suka kamu da cutar GPC3+.

A halin yanzu, akwai wasu gwaje-gwajen asibiti da yawa na CAR-T a China, kuma suna neman marasa lafiya. Don neman shawara kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Kasa da Kasa na Asibitin Oncology na Yankin Kudu na Beijing.

Lambar Waya: 4008803716

Email：myimmnet@163.com